Terry DavidVenture capital has a structural problem in biotechnology that is less often discussed than the high attrition rates or the extended development timelines: the experience gap between the people providing capital and the people trying to deploy it. Most investors in life sciences have built careers evaluating companies from the outside. They understand financial models, they have developed pattern recognition across portfolios, and they have learned which questions to ask in a pitch meeting. What they rarely have is firsthand knowledge of what it actually costs, in time and decision-making pressure, to move a drug candidate from a laboratory bench through regulatory approval. Leen Kawas has spent her career on both sides of that gap, as documented here, and her views on board composition in biotech are shaped by what she found when she crossed it.
Kawas came to the United States from Jordan in 2008 to pursue doctoral research in molecular pharmacology at Washington State University. She co-founded what became Athira Pharma in 2014, co-invented the company’s lead drug candidate, and served as CEO through a September 2020 IPO that raised over $400 million. She was one of only 22 women founders in the United States to have taken a company public at that point, and the first woman in Washington State to do so in more than two decades. That trajectory gave her something that is genuinely unusual in the venture capital industry: she had been the founder-operator in the room when boards made the kinds of decisions that determine whether a biotech company survives a difficult clinical result or a capital market contraction. When she co-founded Propel Bio Partners in 2022, she brought that experience to the other side of the table.
What the Operator Perspective Changes
Leen Kawas has described the difference that founder-operator experience makes in board-level conversations with specificity. Drug development programmes stretch across years and encounter decision points that cannot be fully anticipated at the time of investment. A clinical result that departs from the expected outcome requires the board to assess whether the departure represents a fundamental problem with the scientific thesis or an opportunity to adjust the trial design and preserve the programme. That assessment requires someone who understands the science at a sufficient level of depth to distinguish between the two. It also requires someone who has made that kind of call before, under conditions of genuine uncertainty and with capital on the line.
The traditional venture capital model, as Kawas has framed it, treats investment primarily as a financial transaction: evaluate the science, assess the team, write the check, and monitor progress through quarterly reports. That model works reasonably well for software companies, where the cost of a wrong decision is a failed sprint and the timeline for correction is weeks. Biotech operates differently. A regulatory submission prepared incorrectly is not corrected quickly. A clinical programme that recruits the wrong patient population produces years of data that cannot be repurposed. The decisions that matter most in biotech require board members who understand what they are actually deciding, not just how it will read on the financial model.
Beyond Capital to Capability
At Propel Bio Partners, Kawas has built a model that explicitly extends beyond capital provision. The firm offers operational and technical support to its portfolio companies alongside funding, drawing on the team’s experience in drug discovery, clinical operations, regulatory strategy, and capital markets navigation. She has pointed to the redundancies and conventional practices in the industry that first-time founders often do not know to question: expensive processes that persist because that is how things have always been done rather than because they are the most efficient available approach. A board member with founder-operator experience can identify those redundancies from firsthand observation rather than inferring them from a competitive analysis.
A theme explored in Kawas’s coverage at leenkawas.news is the mindset she looks for in the founders she backs, and the description reflects her own background. She values what she has called a beginner’s mindset: the willingness to approach each problem on its own terms rather than importing the frameworks that produced prior difficulties. She has noted that the most capable founders she has encountered bring both scientific ambition and a genuine openness to being wrong about the path forward. That quality is easier to recognise in a room if you have needed it yourself.
The Board as an Operating Resource
The boards Kawas sits on, including Inherent Biosciences, which applies AI-driven epigenetics to complex health challenges, reflect the same principle applied from the governance side. She has described what she contributes in those roles as an ability to assess life sciences opportunities by drawing on direct experience across drug discovery, clinical trial methodology, and commercialisation strategy, integrated with the perspective of someone who has raised and deployed substantial capital. That integration matters. A board member who understands the science but not the capital markets, or the capital markets but not the science, is providing partial oversight at best.
The wider significance of Leen Kawas on founder-operator board experience has implications that extend beyond any individual company. As the industry faces a period of sustained capital constraint and increased investor selectivity, the boards that will make the best decisions are likely to be the ones that can evaluate scientific and commercial risk with equal depth. Building those boards requires the industry to take seriously the question of who sits in the room and what they actually know. Kawas (see leenkawas.com) has been making that argument consistently, and she has been making it from the most credible possible position: as someone who has been on both sides of the table and understands what each side most needs from the other.
